- Home
- BOLD vs BBBYW Comparison
BOLD vs BBBYW Comparison
Compare BOLD & BBBYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | BBBYW |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Catalog/Specialty Distribution |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 59.2M |
| IPO Year | 2024 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BOLD | BBBYW |
|---|---|---|
| Price | $2.85 | $0.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 110.3K | ★ 277.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.47 | ★ 74.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,044,616,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.52 |
| 52 Week High | $3.16 | $1.20 |
Technical Indicators
Market Signals| Indicator | BOLD | BBBYW |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 55.74 |
| Support Level | $2.71 | N/A |
| Resistance Level | $2.97 | $1.20 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 17.34 | 28.38 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.